Compare Boston Scientific Corporation (BSX) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Entegris Inc — how do they compare? Boston Scientific Corporation trades at $43.32 (market cap $66.37B), while Entegris Inc trades at $139.85 (market cap $21.42B). The key difference: Boston Scientific Corporation is far larger — about 3.1× Entegris Inc's market cap, and Entegris Inc pays a 0.28% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ENTG | |
|---|---|---|
Market Cap | $66.37B | $21.42B |
Sector | Health | Technology |
52-Week High | $108.14 | $184.00 |
52-Week Low | $42.63 | $68.80 |
Enterprise Value | $75.94B | $24.73B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
ENTG trades at $136.27, down 6.25% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 78.77 but strong recent earnings beats. Revenue remains stable at $3.2B with improving net margins. Analyst consensus is bullish with a $178.40 price target, representing 31% upside potential. Recent developments include a new CFO appointment and strategic licensing agreements in semiconductor technology.
ENTG presents a compelling growth story in semiconductor materials with AI-driven demand catalysts, though premium valuation and technical weakness create near-term headwinds. The company's positioning in advanced chip manufacturing and consistent earnings performance support long-term upside, while current price levels offer entry opportunity below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
